Effects of structured exercise programmes on physiological and psychological outcomes in adults with inflammatory bowel disease (IBD): A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
03
2022
accepted:
17
11
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
Exercise has been suggested to counteract specific complications of inflammatory bowel disease (IBD). However, its role as a therapeutic option remains poorly understood. Therefore, we conducted a systematic review and meta-analysis on the effects of exercise in IBD. Five databases (MEDLINE, Embase, CINAHL, CENTRAL and SPORTDiscus) and three registers (Clinicaltrials.gov, WHO ICTRP and ISRCTN) were searched from inception to September 2022, for studies assessing the effects of structured exercise of at least 4 weeks duration on physiological and/or psychological outcomes in adults with IBD. Two independent reviewers screened records, assessed risk of bias using the Cochrane Risk of Bias (RoB 2.0) and ROBINS-I tools, and evaluated the certainty of evidence using the GRADE method. Data were meta-analysed using a random-effects model. From 4,123 citations, 15 studies (9 RCTs) were included, comprising of 637 participants (36% male). Pooled evidence from six RCTs indicated that exercise improved disease activity (SMD = -0.44; 95% CI [-0.82 to -0.07]; p = 0.02), but not disease-specific quality of life (QOL) (IBDQ total score; MD = 3.52; -2.00 to 9.04; p = 0.21) when compared to controls. Although meta-analysis could not be performed for other outcomes, benefits were identified in fatigue, muscular function, body composition, cardiorespiratory fitness, bone mineral density and psychological well-being. Fourteen exercise-related non-serious adverse events occurred. The overall certainty of evidence was low for disease activity and very low for HRQOL as a result of downgrading for risk of bias and imprecision. Structured exercise programmes improve disease activity, but not disease-specific QOL. Defining an optimal exercise prescription and synthesis of evidence in other outcomes, was limited by insufficient well-designed studies to ascertain the true effect of exercise training. This warrants further large-scale randomised trials employing standard exercise prescription to verify this effect to enable the implementation into clinical practice. This systematic review was prospectively registered in an international database of systematic reviews in health-related research (CRD42017077992; https://www.crd.york.ac.uk/prospero/).
Sections du résumé
BACKGROUND
Exercise has been suggested to counteract specific complications of inflammatory bowel disease (IBD). However, its role as a therapeutic option remains poorly understood. Therefore, we conducted a systematic review and meta-analysis on the effects of exercise in IBD.
METHODS
Five databases (MEDLINE, Embase, CINAHL, CENTRAL and SPORTDiscus) and three registers (Clinicaltrials.gov, WHO ICTRP and ISRCTN) were searched from inception to September 2022, for studies assessing the effects of structured exercise of at least 4 weeks duration on physiological and/or psychological outcomes in adults with IBD. Two independent reviewers screened records, assessed risk of bias using the Cochrane Risk of Bias (RoB 2.0) and ROBINS-I tools, and evaluated the certainty of evidence using the GRADE method. Data were meta-analysed using a random-effects model.
RESULTS
From 4,123 citations, 15 studies (9 RCTs) were included, comprising of 637 participants (36% male). Pooled evidence from six RCTs indicated that exercise improved disease activity (SMD = -0.44; 95% CI [-0.82 to -0.07]; p = 0.02), but not disease-specific quality of life (QOL) (IBDQ total score; MD = 3.52; -2.00 to 9.04; p = 0.21) when compared to controls. Although meta-analysis could not be performed for other outcomes, benefits were identified in fatigue, muscular function, body composition, cardiorespiratory fitness, bone mineral density and psychological well-being. Fourteen exercise-related non-serious adverse events occurred. The overall certainty of evidence was low for disease activity and very low for HRQOL as a result of downgrading for risk of bias and imprecision.
CONCLUSIONS
Structured exercise programmes improve disease activity, but not disease-specific QOL. Defining an optimal exercise prescription and synthesis of evidence in other outcomes, was limited by insufficient well-designed studies to ascertain the true effect of exercise training. This warrants further large-scale randomised trials employing standard exercise prescription to verify this effect to enable the implementation into clinical practice.
REGISTRATION
This systematic review was prospectively registered in an international database of systematic reviews in health-related research (CRD42017077992; https://www.crd.york.ac.uk/prospero/).
Identifiants
pubmed: 36454911
doi: 10.1371/journal.pone.0278480
pii: PONE-D-22-06927
pmc: PMC9714897
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0278480Informations de copyright
Copyright: © 2022 Jones et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
KJ, GT and KB were investigators on one if the included trials (Jones et al., 2020) and GT on another (Tew et al., 2019), however we do not believe that this has biased our assessment of this or any other study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Am J Gastroenterol. 2001 Jun;96(6):1822-30
pubmed: 11419836
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1275-80
pubmed: 14624149
Dig Dis Sci. 2021 Feb;66(2):597-604
pubmed: 32239380
Endocrinology. 2017 Mar 1;158(3):664-677
pubmed: 28359087
J Clin Epidemiol. 2006 Jan;59(1):7-10
pubmed: 16360555
Mol Cell Endocrinol. 2011 Dec 5;347(1-2):11-6
pubmed: 21664245
World J Gastroenterol. 2019 Jul 28;25(28):3823-3837
pubmed: 31391776
Am J Gastroenterol. 2002 Nov;97(11):2843-9
pubmed: 12425558
Res Synth Methods. 2017 Sep;8(3):290-302
pubmed: 28378395
Aliment Pharmacol Ther. 2010 Jul;32(2):131-43
pubmed: 20456309
Am J Gastroenterol. 2000 Apr;95(4):1008-13
pubmed: 10763951
J Sports Med Phys Fitness. 2010 Mar;50(1):1-18
pubmed: 20308966
Gastroenterology. 1998 Jul;115(1):36-41
pubmed: 9649456
Exerc Immunol Rev. 2009;15:6-41
pubmed: 19957870
Med Sci Sports Exerc. 2009 Nov;41(11):2037-43
pubmed: 19812513
Diabetologia. 2014 Sep;57(9):1789-97
pubmed: 24996616
Aliment Pharmacol Ther. 2020 Sep;52(6):964-975
pubmed: 33119156
Digestion. 2015;91(3):239-47
pubmed: 25823689
Endocrinology. 2001 Mar;142(3):1290-5
pubmed: 11181547
United European Gastroenterol J. 2020 Aug;8(7):804-813
pubmed: 32580666
Int J Sports Med. 2016 Jun;37(7):505-15
pubmed: 27116344
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
Sports Med. 2018 Apr;48(4):765-785
pubmed: 29372481
PLoS One. 2016 Mar 03;11(3):e0150869
pubmed: 26938879
Aliment Pharmacol Ther. 2017 Jun;45(11):1379-1389
pubmed: 28378342
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
BMC Gastroenterol. 2019 Jul 2;19(1):115
pubmed: 31266461
Am J Gastroenterol. 2011 May;106(5):988-98
pubmed: 21224841
Gastroenterol Clin North Am. 2017 Dec;46(4):797-808
pubmed: 29173522
Am J Gastroenterol. 1999 Mar;94(3):697-703
pubmed: 10086654
Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):585-95
pubmed: 23835489
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Inflamm Bowel Dis. 2011 Sep;17(9):1882-9
pubmed: 21830266
Gut. 2004 Sep;53 Suppl 5:V1-16
pubmed: 15306569
Clin Gastroenterol Hepatol. 2013 Mar;11(3):278-85
pubmed: 23103821
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Afr Health Sci. 2018 Mar;18(1):120-131
pubmed: 29977265
Aliment Pharmacol Ther. 2005 Mar 1;21(5):499-508
pubmed: 15740531
J Crohns Colitis. 2009 Dec;3(4):225-31
pubmed: 21172280
BMC Pediatr. 2019 Aug 27;19(1):297
pubmed: 31455308
Explore (NY). 2022 May-Jun;18(3):335-341
pubmed: 34210638
Proc Nutr Soc. 2004 May;63(2):337-40
pubmed: 15294052
N Engl J Med. 2004 Nov 11;351(20):2045-8
pubmed: 15537904
Dig Dis Sci. 2013 Feb;58(2):293-5
pubmed: 23361569
Ital J Gastroenterol Hepatol. 1999 Apr;31(3):205-10
pubmed: 10379481
J Crohns Colitis. 2014 Dec;8(12):1749-50
pubmed: 25239575
Front Physiol. 2019 May 03;10:536
pubmed: 31130877
Clin Exp Gastroenterol. 2015 Mar 23;8:111-7
pubmed: 25848313
BMC Gastroenterol. 2019 Feb 12;19(1):29
pubmed: 30755154
Inflamm Bowel Dis. 2005 Mar;11(3):296-303
pubmed: 15735436
Can J Gastroenterol. 2008 May;22(5):497-504
pubmed: 18478136
Clin J Sport Med. 2007 Sep;17(5):384-8
pubmed: 17873551
J Crohns Colitis. 2012 Feb;6 Suppl 2:S224-34
pubmed: 22463929
Int J Yoga Therap. 2015;25(1):101-12
pubmed: 26667293
Clin Sci (Lond). 2015 Dec;129(12):1097-105
pubmed: 26265792
Clin Exp Gastroenterol. 2017 May 02;10:83-90
pubmed: 28496351
Am J Med. 2009 Jul;122(7):599-604
pubmed: 19559158
Biomed Res Int. 2014;2014:429031
pubmed: 24877092
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
J Crohns Colitis. 2016 Mar;10(3):239-54
pubmed: 26614685
BMC Gastroenterol. 2019 Jan 29;19(1):19
pubmed: 30696423
Gastroenterol Hepatol (N Y). 2011 Apr;7(4):235-41
pubmed: 21857821
Muscle Nerve. 2015 Oct;52(4):631-9
pubmed: 25594832